SG11202008864VA - Intracellular delivery of biomolecules to modify immune response - Google Patents

Intracellular delivery of biomolecules to modify immune response

Info

Publication number
SG11202008864VA
SG11202008864VA SG11202008864VA SG11202008864VA SG11202008864VA SG 11202008864V A SG11202008864V A SG 11202008864VA SG 11202008864V A SG11202008864V A SG 11202008864VA SG 11202008864V A SG11202008864V A SG 11202008864VA SG 11202008864V A SG11202008864V A SG 11202008864VA
Authority
SG
Singapore
Prior art keywords
biomolecules
immune response
intracellular delivery
modify immune
modify
Prior art date
Application number
SG11202008864VA
Inventor
Scott Loughhead
Leeann Talarico
Alfonso Vicente-Suarez
Matt Booty
Howard Bernstein
Katarina Blagovic
Armon R Sharei
Kelan Hlavaty
Original Assignee
Sqz Biotechnologies Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sqz Biotechnologies Co filed Critical Sqz Biotechnologies Co
Publication of SG11202008864VA publication Critical patent/SG11202008864VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • General Engineering & Computer Science (AREA)
SG11202008864VA 2018-03-12 2019-03-11 Intracellular delivery of biomolecules to modify immune response SG11202008864VA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862641987P 2018-03-12 2018-03-12
US201862738941P 2018-09-28 2018-09-28
US201962794516P 2019-01-18 2019-01-18
PCT/US2019/021705 WO2019178006A2 (en) 2018-03-12 2019-03-11 Intracellular delivery of biomolecules to modify immune response

Publications (1)

Publication Number Publication Date
SG11202008864VA true SG11202008864VA (en) 2020-10-29

Family

ID=66102189

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008864VA SG11202008864VA (en) 2018-03-12 2019-03-11 Intracellular delivery of biomolecules to modify immune response

Country Status (16)

Country Link
EP (1) EP3765068A2 (en)
JP (1) JP2021517813A (en)
KR (1) KR20200130835A (en)
CN (1) CN112135627A (en)
AU (1) AU2019234550A1 (en)
BR (1) BR112020018612A2 (en)
CA (1) CA3093828A1 (en)
CO (1) CO2020012584A2 (en)
CR (1) CR20200460A (en)
IL (1) IL277188A (en)
MA (1) MA52010A (en)
MX (1) MX2020009439A (en)
PH (1) PH12020551436A1 (en)
SG (1) SG11202008864VA (en)
TW (1) TW202003019A (en)
WO (1) WO2019178006A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11613759B2 (en) 2015-09-04 2023-03-28 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
JP6884450B2 (en) * 2019-02-14 2021-06-09 学校法人獨協学園獨協医科大学 T cell vaccine
EP3931309A4 (en) 2019-02-28 2022-12-21 SQZ Biotechnologies Company Delivery of biomolecules to pbmcs to modify an immune response
CN113840906A (en) 2019-04-08 2021-12-24 Sqz生物技术公司 Kits for use in a system for delivering a payload into a cell
CN115551540A (en) 2020-05-11 2022-12-30 豪夫迈·罗氏有限公司 Combination therapy using modified PBMCs and immunoconjugates
WO2022026620A1 (en) 2020-07-29 2022-02-03 Sqz Biotechnologies Company Methods to stimulate immune responses to mutant ras using nucleated cells
CN116322752A (en) 2020-07-29 2023-06-23 Sqz生物技术公司 Methods of stimulating immune responses to mutant RAS using anuclear cells
CN117042796A (en) 2020-12-29 2023-11-10 Sqz生物技术公司 Method of treating cancer with activating antigen carrier
TW202241465A (en) 2020-12-29 2022-11-01 美商Ｓｑｚ生物科技公司 Formulations of pbmcs
CA3203709A1 (en) 2020-12-29 2022-07-07 Sqz Biotechnologies Company Formulations of activating antigen carriers
US20220233677A1 (en) 2020-12-29 2022-07-28 Sqz Biotechnologies Company Methods for treating cancers with modified pbmcs
CN115252772A (en) * 2021-04-30 2022-11-01 华普生物技术(江苏)股份有限公司 Application of artificially synthesized deoxyoligonucleotide containing CpG single strand in vaccine
WO2023010090A1 (en) 2021-07-29 2023-02-02 Sqz Biotechnologies Company Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery
WO2023087009A1 (en) 2021-11-11 2023-05-19 Sqz Biotechnologies Company Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery
WO2024026492A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Methods for treating cancer with enhanced antigen presenting cells
WO2024026491A2 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Enhanced antigen presenting cell formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005060993A1 (en) * 2003-12-24 2005-07-07 Leiden University Medical Center Synthetic protein as tumor-specific vaccine
ES2482192T3 (en) * 2007-05-31 2014-08-01 Academisch Ziekenhuis Leiden H.O.D.N. Lumc HPV Peptide Intradermal Vaccination
ES2679043T3 (en) * 2009-05-15 2018-08-21 Irx Therapeutics, Inc. Vaccine immunotherapy
RU2656156C2 (en) 2011-10-17 2018-05-31 Массачусетс Инститьют Оф Текнолоджи Intracellular delivery
CN107109362A (en) * 2014-10-31 2017-08-29 麻省理工学院 Biomolecule is delivered to immunocyte
PL3344747T3 (en) 2015-09-04 2023-06-19 Sqz Biotechnologies Company Intracellular delivery of biomolecules mediated by a surface with pores
CN116218916A (en) * 2016-01-12 2023-06-06 Sqz生物技术公司 Intracellular delivery of complexes

Also Published As

Publication number Publication date
AU2019234550A1 (en) 2020-10-01
MA52010A (en) 2021-01-20
JP2021517813A (en) 2021-07-29
EP3765068A2 (en) 2021-01-20
RU2020132504A3 (en) 2022-04-13
CN112135627A (en) 2020-12-25
CR20200460A (en) 2020-11-23
CO2020012584A2 (en) 2020-11-20
TW202003019A (en) 2020-01-16
RU2020132504A (en) 2022-04-13
KR20200130835A (en) 2020-11-20
WO2019178006A3 (en) 2019-11-07
PH12020551436A1 (en) 2021-09-06
BR112020018612A2 (en) 2020-12-29
WO2019178006A2 (en) 2019-09-19
CA3093828A1 (en) 2019-09-19
IL277188A (en) 2020-10-29
MX2020009439A (en) 2021-01-08

Similar Documents

Publication Publication Date Title
IL277188A (en) Intracellular delivery of biomolecules to modify immune response
IL262677A (en) Intracellular delivery of biomolecules to induce tolerance
IL262676A (en) Intracellular delivery of biomolecules to induce tolerance
IL285809A (en) Delivery of biomolecules to pbmcs to modify an immune response
IL261188A (en) Antibodies to tigit
IL252005B (en) Delivery of biomolecules to immune cells
IL269499A (en) Stable antibody formulation
IL268881A (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
PL3344747T3 (en) Intracellular delivery of biomolecules mediated by a surface with pores
SG11201608207XA (en) Immune balance regulator
IL268731A (en) New uses of anti-sirpg antibodies
IL261065A (en) Tgfbeta 2 antibodies
HK1256033A1 (en) Use of peptides to stimulate the immune system
GB201609742D0 (en) Improvements relating to antibodies
DK3191515T3 (en) LIGANDS THAT INCREASE THE BIOACTIVITY OF GONADOTROPINES
LU92637B1 (en) Capsule to contain powder preparation therein
DK3380120T3 (en) IMMUNE STIMULATING COMPOSITIONS
IL274231A (en) Modulators of enac expression
IL272933A (en) Preparation of solid dosage forms comprising antibodies by solution/ suspension layering
IL269169A (en) Novel dosage form
PL3524231T3 (en) Stabilized preparation of interferon beta variant
SG10201700022QA (en) Intradermal Administration Of Immunoglobulin G Preparation
IL272015A (en) Antibodies to MADCAM
ZA202100026B (en) Complex for enhancing immune response
RS20170960A1 (en) Preparation of products with stable parthenolde contentent